Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension

Canadian Journal of Cardiology

Volumn 31, Issue 4, 2015, Pages 407-415

  Vaillancourt, Mylène ^a   Ruffenach, Grégoire ^a   Meloche, Jolyane ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; LONG UNTRANSLATED RNA; MICRORNA; STAT3 PROTEIN;

ADAPTATION; ANGIOGENESIS; APOPTOSIS; ARTERIOLE; AUTOIMMUNITY; BLOOD VESSEL WALL; CELL DAMAGE; CELL PROLIFERATION; DENDRITIC CELL; DEREGULATION; DNA DAMAGE; DNA METHYLATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENVIRONMENTAL STRESS; EPIGENETICS; FIBROBLAST; HISTONE MODIFICATION; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LUNG CIRCULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOLECULAR MECHANICS; PARACRINE SIGNALING; PHENOTYPE; PULMONARY ARTERY; PULMONARY ARTERY REMODELLING; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; STRESS; VASOCONSTRICTION; VASODILATATION;

EID: 84964285738     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.10.023     Document Type: Review

References (80)

1. Runo J.R., Loyd J.E. Primary pulmonary hypertension. Lancet 2003, 361:1533-1544.
2. Montani D., Günther S., Dorfmüller P., et al. Pulmonary arterial hypertension. Orphanet J Rare Dis 2013, 8:97.
3. Wojciak-Stothard B., Abdul-Salam V.B., Lao K.H., et al. Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension. Circulation 2014, 129:1770-1780.
4. Dickinson M.G., Bartelds B., Borgdorff M.A., Berger R.M. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol 2013, 305:L1-L14.
5. Rabinovitch M., Guignabert C., Humbert M., Nicolls M.R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014, 115:165-175.
6. Stacher E., Graham B.B., Hunt J.M., et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:261-272.
7. Liao J.K. Linking endothelial dysfunction with endothelial cell activation. JClin Invest 2013, 123:540-541.
8. Newby A.C. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006, 69:614-624.
9. Lannan K.L., Phipps R.P., White R.J. Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today 2014, 19:1230-1235.
10. Thomas M., Ciuclan L., Hussey M.J., Press N.J. Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension. Pharmacol Ther 2013, 138:409-417.
11. Li M., Liu Y., Jin F., et al. Endothelin-1 induces hypoxia inducible factor 1α expression in pulmonary artery smooth muscle cells. FEBS Lett 2012, 586:3888-3893.
12. Xia Y., Fu Z., Hu J., et al. TRPV4 channel contributes to serotonin-induced pulmonary vasoconstriction and the enhanced vascular reactivity in chronic hypoxic pulmonary hypertension. Am J Physiol Cell Physiol 2013, 305:C704-C715.
13. Kuhr F.K., Smith K.A., Song M.Y., Levitan I., Yuan J.X. New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling. Am J Physiol Heart Circ Physiol 2012, 302:H1546-H1562.
14. Klinger J.R., Abman S.H., Gladwin M.T. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013, 188:639-646.
15. Guignabert C., Alvira C.M., Alastalo T.P., et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1082-L1090.
16. Wolf D., Tseng N., Seedorf G., et al. Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2014, 306:L361-L371.
17. Potus F., Malenfant S., Graydon C., et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014, 190:318-328.
18. Ma J., Zhang L., Han W., et al. Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells. JLipid Res 2012, 53:1093-1105.
19. Jonigk D., Golpon H., Bockmeyer C.L., et al. Plexiform lesions in pulmonary arterial hypertension. Am J Pathol 2011, 179:167-179.
20. Abe K., Toba M., Alzoubi A., et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010, 121:2747-2754.
21. Lavoie J.R., Ormiston M.L., Perez-Iratxeta C., et al. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation 2014, 129:2125-2135.
22. Li M., Vattulainen S., Aho J., et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2014, 50:1118-1128.
23. Kherbeck N., Tamby M.C., Bussone G., et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol 2013, 44:31-38.
24. Cuttica M.J., Langenickel T., Noguchi A., et al. Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. Am J Respir Cell Mol Biol 2011, 45:62-71.
25. Ulrich S., Taraseviciene-Stewart L., Huber L.C., Speich R., Voelkel N. Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res 2008, 9:20.
26. Savai R., Pullamsetti S.S., Kolbe J., et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:897-908.
27. Tian W., Jiang X., Tamosiuniene R., et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med 2013, 5:200ra117.
28. Vergadi E., Chang M.S., Lee C., et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 2011, 123:1986-1995.
29. Satoh K., Satoh T., Kikuchi N., et al. Basigin mediates pulmonary hypertension by promoting inflammation and vascular smooth muscle cell proliferation. Circ Res 2014, 115:738-750.
30. Jin H., Wang Y., Zhou L., et al. Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells. JPineal Res 2014, 57:442-450.
31. Price L.C., Caramori G., Perros F., et al. Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PloS One 2013, 8:e75415.
32. Ricard N., Tu L., Le Hiress M., et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. Circulation 2014, 129:1586-1597.
33. Golembeski S.M., West J., Tada Y., Fagan K.A. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 2005, 128(6 suppl):572S-573S.
34. Paulin R., Meloche J., Jacob M.H., et al. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2011, 301:H1798-H1809.
35. Courboulin A., Tremblay V.L., Barrier M., et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011, 12:128.
36. Lawrie A., Waterman E., Southwood M., et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 2008, 172:256-264.
37. Sutendra G., Dromparis P., Bonnet S., et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. JMol Med 2011, 89:771-783.
38. Crosswhite P., Chen K., Sun Z. AAV delivery of tumor necrosis factor-α short hairpin RNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling. Hypertension 2014, 64:1141-1150.
39. Perros F., Dorfmüller P., Souza R., et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007, 29:937-943.
40. Malenfant S., Neyron A.S., Paulin R., et al. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ 2013, 3:278-293.
41. Sakao S., Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol 2011, 147:4-12.
42. Paulin R., Courboulin A., Barrier M., Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. JMol Med (Berl) 2011, 89:1089-1101.
43. Brock M., Trenkmann M., Gay R.E., et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009, 104:1184-1191.
44. Wu W.Y., Kim H., Zhang C.L., Meng X.L., Wu Z.S. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma. JInvest Surg 2014, 27:197-204.
45. Chen Q., Jin M., Yang F., et al. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013, 2013:928315.
46. Schermuly R.T., Dony E., Ghofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. JClin Invest 2005, 115:2811-2821.
47. Paulin R., Meloche J., Courboulin A., et al. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J 2014, 43:531-544.
48. Paulin R., Courboulin A., Meloche J., et al. Signal transducers and activators of transcription-3/Pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011, 123:1205-1215.
49. Masri F.A., Xu W., Comhair S.A., et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007, 293:L548-L554.
50. Courboulin A., Barrier M., Perreault T., et al. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J 2012, 40:618-629.
51. Courboulin A., Paulin R., Giguère N.J., et al. Role for miR-204 in human pulmonary arterial hypertension. JExp Med 2011, 208:535-548.
52. Renard S., Paulin R., Breuils-Bonnet S., et al. Pim-1: a new biomarker in pulmonary arterial hypertension. Pulm Circ 2013, 3:74-81.
53. Hoeper M.M., Barst R.J., Bourge R.C., et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013, 127:1128-1138.
54. Kantarjian H., Shah N.P., Cortes J.E., et al. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION (abstract). ASCO Meeting Abstracts 2011, 29(15 suppl):6510.
55. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEngl J Med 2010, 362:2251-2259.
56. Meloche J., Pflieger A., Vaillancourt M., et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014, 129:786-797.
57. Zhao L., Ashek A., Wang L., et al. Heterogeneity in lung 18FDG uptake in pulmonary arterial hypertension potential of dynamic 18FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 2013, 128:1214-1224.
58. Sutendra G., Dromparis P., Wright P., et al. The role of nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med 2011, 3:88ra55.
59. Sutendra G., Michelakis E.D. The metabolic basis of pulmonary arterial hypertension. Cell Metab 2014, 19:558-573.
60. Archer S.L., Marsboom G., Kim G.H., et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010, 121:2661-2671.
61. Zhao L., Chen C.N., Hajji N., et al. Histone deacetylation inhibition in pulmonary hypertension therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012, 126:455-467.
62. Meloche J., Pflieger A., Vaillancourt M., et al. miRNAs in PAH: biomarker, therapeutic target or both?. Drug Discov Today 2014, 19:1264-1269.
63. Potus F., Graydon C., Provencher S., Bonnet S. Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ 2014, 4:175-184.
64. Bockmeyer C.L., Maegel L., Janciauskiene S., et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. JHeart Lung Transplant 2012, 31:764-772.
65. Parikh V.N., Jin R.C., Rabello S., et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012, 125:1520-1532.
66. Bertero T., Lu Y., Annis S., et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. JClin Invest 2014, 124:3514-3528.
67. Kanda T., Brown J.D., Orasanu G., et al. PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. JClin Invest 2009, 119:110-124.
68. Caruso P., Dempsie Y., Stevens H.C., et al. Arole for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012, 111:290-300.
69. Potus F., Graydon C., Bonnet S.B., et al. Mir-126 dependent alteration of angiogenesis contributes to right ventricle failure in pulmonary arterial hypertension (868.2). FASEB J 2014, 28(suppl 1):868.2.
70. Sarkar J., Gou D., Turaka P., et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010, 299:L861-L871.
71. Sharma S., Umar S., Potus F., et al. Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p. Circulation 2014, 130:776-785.
72. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013, 31:577.
73. Janssen H.L., Reesink H.W., Lawitz E.J., et al. Treatment of HCV infection by targeting microRNA. NEngl J Med 2013, 368:1685-1694.
74. Bonnet S., Michelakis E.D., Porter C.J., et al. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006, 113:2630-2641.
75. Archer S.L., Souil E., Dinh-Xuan A.T., et al. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. JClin Invest 1998, 101:2319-2330.
76. Galletti M., Cantoni S., Zambelli F., et al. Dissecting histone deacetylase role in pulmonary arterial smooth muscle cell proliferation and migration. Biochem Pharmacol 2014, 91:181-190.
77. Bogaard H.J., Mizuno S., Hussaini A.A., et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011, 183:1402-1410.
78. Mercer T.R., Dinger M.E., Mattick J.S. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009, 10:155-159.
79. Michalik K.M., You X., Manavski Y., et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014, 114:1389-1397.
80. Wu G., Cai J., Han Y., et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis and atherosclerosis by enhancing p53 activity. Circulation 2014, 130:1452-1456.